The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
Alexander E. Drilon
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Genentech/Roche; Ignyta; Loxo; Pfizer; Takeda; TP Therapeutics
Vivek Subbiah
Consulting or Advisory Role - MedImmune
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; PharmaMar
Geoffrey R. Oxnard
Honoraria - Bio-Rad; Chugai Pharma; Guardant Health; Sysmex
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; DropWorks; Genentech/Roche; GRAIL; Ignyta; Inivata; LOXO; Novartis; Takeda
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst)
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Consulting or Advisory Role - Guardant Health; Ignyta (Inst); Loxo; Moderna Therapeutics (Inst); Pfizer
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Medpacto, Inc. (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Peleton (Inst); Pfizer (Inst); Principa Biopharma (Inst); Principa Biopharma (Inst); Roche (Inst); Sanofi (Inst); Stemline Therapeutics (Inst)
Vamsidhar Velcheti
Honoraria - Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; Merck; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Foundation Medicine; Genentech; Genoptix; Merck; Takeda
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantOmics (Inst); OncoPlex Diagnostics (Inst); Trovagene (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Foundation Medicine; Merck
Nehal J. Lakhani
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Amgen (Inst); ArQule (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Dicerna (Inst); Forty Seven (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst)
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Inivata (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); OncoMed (Inst); Onxeo (Inst); ose pharma (Inst); ose pharma (Inst); Pfizer (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca
Maria E. Cabanillas
Consulting or Advisory Role - Blueprint Medicines; Loxo
Research Funding - Eisai; Exelixis; Kura; Roche/Genentech
Melissa Lynne Johnson
Consulting or Advisory Role - Astellas Pharma (I); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Genentech/Roche (Inst); Otsuka (I)
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Genmab (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Tarveda Therapeutics (Inst)
Karen L. Reckamp
Consulting or Advisory Role - Amgen; ARIAD; Astellas Pharma; Boehringer Ingelheim; Euclises; Takeda; Tesaro
Research Funding - Abbvie; Adaptimmune (Inst); ARIAD (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Xcovery (Inst)
Valentina Boni
No Relationships to Disclose
Herbert H. F. Loong
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Roche/Genentech
Speakers' Bureau - Abbvie; Ignyta; Novartis
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Pfizer; Roche
Martin Schlumberger
Consulting or Advisory Role - Bayer; Eisai; Ipsen; Sanofi
Research Funding - N/A (Inst)
Ben Solomon
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Novartis; Roche
Patents, Royalties, Other Intellectual Property - Biodesix; UpToDate
Scott Cruickshank
Consulting or Advisory Role - Loxo
Stephen M. Rothenberg
Employment - Loxo
Stock and Other Ownership Interests - Loxo
Manisha H. Shah
Consulting or Advisory Role - Eisai; Loxo; Novartis
Research Funding - Eisai; Loxo; Merck
Lori J. Wirth
Consulting or Advisory Role - Amgen; Blueprint Medicines; Eisai; Loxo; Merck; Novartis